NEWS &
EVENTS
R E S E A R C H N E W S
Celebrating Dr. Robert Damoiseaux: 2024 SLAS Fellow
Dr. Robert Damoiseaux, our UCLA lead, has been recognized as a 2024 fellow from the Society for Laboratory Automation and Screening (SLAS). The SLAS Fellow Program recognizes the exceptional contributions of SLAS's most dedicated contributors. SLAS Fellow Members represent the mission of SLAS, which serves life sciences professionals via practitioner-driven knowledge, education, and peer-to-peer connections. Candidates are selected based on their technical content contribution and volunteer service within the Society. UCDDC is privileged to have such a highly dedicated scientist on our team. Congratulations Robert!
UCD News- Training in Neurotherapeutics Discovery and Development for academics
UCDCC partner campus UC-Davis will hold this year’s annual 4-day training program in Neurotherapeutics Discovery and Development for academic scientists on March 28th-31st at the UC Davis Conference Center. This program is open to advanced post-docs and faculty at all levels and there are no tuition, registration or travel fees required for successful applicants. The training will equip participants with a broad understanding of the various steps in the neurotherapeutics drug discovery and development process including; target identification, assay design, principals of medicinal chemistry, animal efficacy testing, ADME/toxicology studies and IND document preparation. This training program is supported by a grant from the National Institute of Neurological Disorders and Stroke.Deadline to apply: Monday, January 24th- 2022.
UCSC News- UC Santa Cruz Joins the University of California Drug Discovery Consortium
We are happy to announce that UC Santa Cruz has UCDDC. Scott Lokey, professor of chemistry and biochemistry and director of the UCSC Chemical Screening Center, is the UCSC campus lead and a member of the UC DDC executive committee.
Pharmafile - Merck and UCLA Find New COVID-19 Treatment Candidate
Our UCLA campus lead Professor Robert Damoiseaux and his research team discover compounds that could treat COVID-19. This incredible work was published in the journal Cell Reports and highlighted in a Pharmafile article.
NBC-Where Are The Cures For Covid-19?
Our very own Dr. Julia Schaletzky and her team were highlighted on NBC news. Dr. Schaletzky and her team tested Remdesivir in combination with thousands of approved drugs to see if just one would make Remdesivir better at killing the virus.
Translational Research at UCSD Tackles Inflammatory Disease With Promise of a New Peptide Therapeutic
Professor Alessandra Franco, MD, PhD, of the University of California, San Diego, leads researchers in identifying Fc peptides that promote adaptive immune regulation and provide a novel alternative to current autoimmune disease therapeutics.
UCD Researchers Create Cell-Free Regenerative Therapy Utilizing UC DDC Seed Grant Award
Early research originating from the laboratory of Johnathon Anderson, PhD, at the University of California, Davis, Medical Center shows the promise of utilizing exosomes as a new therapeutic platform to treat neurological and cardiovascular diseases.
UCSF Researchers Design Novel Pin-1 Inhibitor as a Result of UC DDC Seed Grant Award
Towards the mission of fighting cancer through drug discovery, Jason Gestwicki, PhD, at the University of California, San Francisco, has led his team to discover a first-in-class Pin1 inhibitor.
C O N S O R T I U M
M I L E S T O N E S
U C D D C E V E N T S
The UC DDC and its participating campuses and organizations provides a wide array of drug discovery-related symposia, seminars, and other events that are open to faculty, staff, and trainees across the UC.
S Y M P O S I A & S E M I N A R S
​
R E L A T E D E V E N T S
​
P R E V I O U S E V E N T S
D R U G D I S C O V E R Y W O R K S H O P S
As part of its core mission, the UC DDC has hosted a number of hands-on learning experiences for staff and trainees across the UC system. Stay tuned for announcements regarding future events.
​
P R E V I O U S E V E N T S
